Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

NCT06333951 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06333951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06333951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 17, 2024
Completion date
November 30, 2026
Enrollment
49 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, thoracic tumors